for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Pfizer And Biontech Propose Expansion Of Pivotal Covid-19 Vaccine Trial

Sept 12 (Reuters) - BioNTech SE:

* PFIZER AND BIONTECH PROPOSE EXPANSION OF PIVOTAL COVID-19 VACCINE TRIAL

* PFIZER - SUBMITTED AMENDED PROTOCOL TO U.S. FDA TO EXPAND ENROLLMENT OF PHASE 3 PIVOTAL COVID-19 VACCINE TRIAL TO UP TO ABOUT 44,000 PARTICIPANTS

* PFIZER - ENROLLMENT IN TRIAL HAS BEEN PROCEEDING AS PLANNED AND COMPANY EXPECTS TO REACH ITS INITIAL TARGET OF UP TO 30,000 PARTICIPANTS NEXT WEEK

* PFIZER - PROPOSED EXPANSION WOULD ALLOW THE COMPANIES TO FURTHER INCREASE TRIAL POPULATION DIVERSITY

* PFIZER - COMPANIES CONTINUE TO EXPECT THAT A CONCLUSIVE READOUT ON EFFICACY IS LIKELY BY THE END OF OCTOBER Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up